IRF4 and neoplasm: A large-scale analysis of DNA methylation further revealed that co-treatment with both drugs alters promoter methylation of a specific set of genes, leading to the identification and functional characterization of IRF4, found to possess tumor suppressor activity in BC and derepressed in this context.